Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CRVS
$18.0716
$
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Next Earnings
2026-02-25
Beta
0.747
Average Volume
Market Cap
Last Dividend
CIK
0001626971
ISIN
US2210151005
CUSIP
221015100
CEO
Richard A. Miller
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
31
IPO Date
2016-03-23
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. | GlobeNewsWire | 2026-02-23 16:01:00 |
| Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 | Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark. | MarketBeat | 2026-02-02 10:39:08 |
| Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why | CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib. | Zacks Investment Research | 2026-01-27 13:15:24 |
| Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know | Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out. | Zacks Investment Research | 2026-01-27 13:01:09 |
| Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet | The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | Zacks Investment Research | 2026-01-27 10:56:09 |
| Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. | GlobeNewsWire | 2026-01-23 17:00:00 |
| Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains | Corvus Pharmaceuticals (NASDAQ: CRVS) presented new Phase I results for oral soquelitinib in moderate-to-severe atopic dermatitis (AD), highlighting updated efficacy, durability, and safety findings from a blinded, placebo-controlled U.S. study that included patients with prior systemic therapy exposure. Cohort 4 corroborates earlier signals with eight-week dosing Chief Executive Officer Richard Miller said the company's newly reported | Defense World | 2026-01-23 03:02:53 |
| Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the shares of common stock are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,185,101 shares of common stock at the public offering price, less underwriting discounts and commissions. | GlobeNewsWire | 2026-01-21 22:53:00 |
| Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon | Corvus Pharmaceuticals, Inc. reported highly positive phase 1 cohort 4 data for soquelitinib in moderate-to-severe atopic dermatitis. 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including for patients previously treated with other therapies. | Seeking Alpha | 2026-01-21 14:50:39 |
| Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know | Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund pivotal Phase 2/3 trials, with durability of response as the next critical catalyst. | Seeking Alpha | 2026-01-21 11:43:48 |
| Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data | Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026. | The Motley Fool | 2026-01-20 17:57:28 |
| Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript | Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript | Seeking Alpha | 2026-01-20 17:15:58 |
| Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. | GlobeNewsWire | 2026-01-20 16:01:00 |
| What made Corvus stock double on Tuesday and is it sustainable? | Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis. Soquelitinib demonstrated strong efficacy in treatment-resistant patients and a “favourable” safety profile, sparking chatter about “best-in-class” potential in the massive dermatology market. | Invezz | 2026-01-20 14:10:24 |
| Corvus Stock Spikes On Heels Of Strong Eczema Study Results | Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis. | Benzinga | 2026-01-20 14:00:10 |
| Why Small Biotech Stock Corvus Pharma Just Launched To An Eight-Year High | Biotech stock Corvus Pharmaceuticals catapulted to an eight-year high Tuesday on promising results in eczema treatment. | Investors Business Daily | 2026-01-20 10:06:52 |
| Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of | Globe News Wire | 2026-01-20 07:00:00 |
| Critical Analysis: Tenaya Therapeutics (NASDAQ:TNYA) vs. Corvus Pharmaceuticals (NASDAQ:CRVS) | Corvus Pharmaceuticals (NASDAQ: CRVS - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Institutional and Insider Ownership 46.6% of Corvus | Defense World | 2026-01-19 02:10:43 |
| Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT | GlobeNewsWire | 2026-01-16 16:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13D/A | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13D/A | 2026-01-27 | 2026-01-27 | View Filing |
| 8-K | 2026-01-23 | 2026-01-23 | View Filing |
| 424B5 | 2026-01-23 | 2026-01-23 | View Filing |
| S-3MEF | 2026-01-21 | 2026-01-21 | View Filing |
| 424B5 | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 10-Q | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-11-04 | 2025-11-04 | View Filing |
| SC 13G | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-06 | 2025-10-06 | View Filing |
| 3 | 2025-10-06 | 2025-10-06 | View Filing |
| 8-K | 2025-10-02 | 2025-10-02 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-07-01 | 2025-07-01 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-04 | 2025-06-04 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13D/A | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-09 | 2025-05-09 | View Filing |
| S-8 | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13D/A | 2025-05-01 | 2025-05-01 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-09 | 2025-04-09 | View Filing |
| 3 | 2025-04-09 | 2025-04-09 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| 10-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 4 | 2024-12-23 | 2024-12-23 | View Filing |
| 8-K | 2024-12-18 | 2024-12-18 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-10-23 | 2024-10-23 | View Filing |
| EFFECT | 2024-08-16 | 2024-08-16 | View Filing |
| S-3 | 2024-08-06 | 2024-08-06 | View Filing |
| 10-Q | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| SC 13G/A | 2024-08-01 | 2024-08-01 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 4 | 2024-06-17 | 2024-06-17 | View Filing |
| 8-K | 2024-06-14 | 2024-06-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| SC 13G/A | 2024-05-13 | 2024-05-13 | View Filing |
| SC 13G | 2024-05-09 | 2024-05-09 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| 4 | 2024-05-08 | 2024-05-08 | View Filing |
| SC 13D/A | 2024-05-08 | 2024-05-08 | View Filing |
| S-8 | 2024-05-07 | 2024-05-07 | View Filing |
| 10-Q | 2024-05-07 | 2024-05-07 | View Filing |
| 4 | 2024-05-07 | 2024-05-07 | View Filing |
| 4 | 2024-05-07 | 2024-05-07 | View Filing |
| 8-K | 2024-05-06 | 2024-05-06 | View Filing |
| 8-K | 2024-05-06 | 2024-05-06 | View Filing |
| 424B5 | 2024-05-03 | 2024-05-03 | View Filing |
| 8-K | 2024-05-01 | 2024-05-01 | View Filing |
| DEFA14A | 2024-04-26 | 2024-04-26 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| 10-K | 2024-03-19 | 2024-03-19 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
| 4 | 2024-03-01 | 2024-03-01 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 84.49% | 0.99 | 166 | 0.07 | 0.18 | 76.43 |
| Bull Bias | 82.29% | 1 | 856 | 0.04 | 0.09 | 74.24 |
| Mean Reversion Strategy | 40.05% | 1.01 | 507 | 0.03 | 0.07 | 31.99 |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |